Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an ...
BioPharma Dive

Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease

The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group ...
Business Insider

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc., a biotechnology company advancing a novel RNA Overwriting platform, today announced the peer-reviewed publication of preclinical ...

RNA tech could make fast test for Alzheimer's disease

One of the most frightening things about Alzheimer's disease is how difficult it is to diagnose early. Now, University of ...
TMCnet

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is ...
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...